LianBio Q1 net loss narrows to $27.7M; cash $389.1M; mavacamten FDA approval

LianBio

2022-Q1 EPS reported -$0.26

Net loss of $27.7M vs $61.6M in Q1 2021; R&D expenses fell to $12.3M from $53.4M.
Cash balance $389.1M as of March 31, 2022; runway projected through mid-2024.
Partner BMS received U.S. FDA approval for mavacamten in obstructive HCM in April 2022.
Partner Tarsus reported positive Phase 3 Saturn-2 data for TP-03 in Demodex blepharitis; NDA planned H2 2022.
Pfizer agreed to acquire development partner ReViral (sisunatovir); LianBio expects to start three Phase 3 trials in China by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.